FDA signs off on Vandas Bysanti for schizophrenia and bipolar I Now in February, the agency has issued another new drug approval to Vanda, signing off on Bysanti as a first-line treatment for schizophrenia or for manic or mixed episodes associated with
US FDA approves Vandas antipsychotic pill, shares climb Feb 20 (Reuters) - The U S Food and Drug Administration has approved Vanda Pharmaceuticals' (VNDA O) drug for the treatment of two serious mental health conditions, the company said on Friday,
Vanda Pharmaceuticals Faces Setbacks as CEO Mihael . . . - StocksToTrade Key Takeaways CEO of Vanda Pharmaceuticals, Mihael Polymeropoulos, offloaded 156,235 shares on March 2, 2026, while still controlling a significant portion of the company’s shares The European medicines agency rejected Vanda’s iloperidone medication for schizophrenia and bipolar disorders, impacting its potential market in Europe
Vanda Pharmaceuticals (VNDA) Stock Price, News Analysis Vanda Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders and rare diseases
Vanda - Wikipedia Vanda, abbreviated in the horticultural trade as V ,[3] is a genus in the orchid family, Orchidaceae There are 90 species, [2] and the genus is commonly cultivated for the marketplace